Terumo expects to recognize losses related to the termination of the supply agreement with major customer CSL Plasma. The consolidated full-year earnings forecast for the fiscal year ending March 2027 has been revised downward to sales of 1,229,500 hundred million yen, adjusted operating income of 274,500 hundred million yen, operating income of 160,000 hundred million yen, net income attributable to owners of parent of 120,000 hundred million yen, and earnings per share of 81.35 yen. Impairment and related losses are expected to be approximately 61 million USD.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4543","jir_company_name":"Terumo Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4543-20261008-01.pdf","jir_short_summary":"Terumo expects to recognize losses related to the termination of the supply agreement with major customer CSL Plasma. The consolidated full-year earnings forecast for the fiscal year ending March 2027 has been revised downward to sales of 1,229,500 hundred million yen, adjusted operating income of 274,500 hundred million yen, operating income of 160,000 hundred million yen, net income attributable to owners of parent of 120,000 hundred million yen, and earnings per share of 81.35 yen. Impairment and related losses are expected to be approximately 61 million USD.","jir_summary":"### Overview of Performance\nTerumo has decided to terminate the supply agreement with major customer CSL Plasma and, after revising future revenue plans, announced it expects total losses of approximately 61 million USD, including impairment of related assets. In response, the consolidated full-year earnings forecast for the fiscal year ending March 2027 has been revised: sales are expected to be approximately 1,229,500 hundred million yen, adjusted operating income approximately 274,500 hundred million yen, operating income approximately 160,000 hundred million yen, net income attributable to owners of parent approximately 120,000 hundred million yen, and dividend per share is expected to be 81.35 yen. Business losses during the transition period are also reflected.\n\n### Future Response and Impact\nTerumo will continue to invest in blood and cell technologies and strengthen solution provision to blood centers, medical institutions, and cell therapy fields. The recognized impairment has disclosed financial impacts that may affect future capital plans and investment decisions.","jir_financial_highlights":"Revenue: 1,239,000 hundred million yen (Vs. previous forecast -0.8%)\nAdjusted Operating Income: 274,500 hundred million yen (Vs. previous forecast 0% (reflects impact of revision))\nOperating Income: 257,500 hundred million yen (Vs. previous forecast -)\nNet Income Attributable to Owners of Parent: 193,100 hundred million yen (Vs. previous forecast -37.9%)\nEarnings Per Share: 130.91 yen (Vs. previous forecast -37.9%)","jir_category":"","jir_hashtags":"#Terumo, #EarningsRevision","jir_key_figures":"Revenue: 1,239,000 hundred million yen\nOperating Income: 257,500 hundred million yen\nNet Income Attributable to Owners of Parent: 193,100 hundred million yen","jir_meta_title":"Terumo Corporation: Recognition of Losses from Major Customer Contract Termination and Full-Year Forecast Revision | October 2026","jir_meta_description":"Terumo Corporation expects to recognize approximately 61 million USD in losses due to termination of the supply agreement with CSL Plasma. The consolidated full-year forecast for the fiscal year ending March 2027 has been revised to sales of 1,239,000 hundred million yen and operating income of 160,000 hundred million yen.","jir_og_title":"Terumo Corporation | Major Contract Termination Impacts Financials, Revises Full-Year Forecast","jir_og_description":"Terumo Corporation anticipates losses related to the termination of the agreement with CSL Plasma and has revised its consolidated full-year forecast for the fiscal year ending March 2027 downward. Check the latest financial impact.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-128645","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n